Table 4 Results from translation, divergent and concurrent validity evidence
From: Validity and reliability of the FSS in Greek MS patients
Study | Translation | Divergent | Concurrent | ||
|---|---|---|---|---|---|
(patients vs non patients) | FSS & Vitality | FSS & PF | FSS & BDI | ||
MS Patients | |||||
Present study | OK | Significant | -0.72 | -0.67 | 0.55 |
Armotlu et al. | OK | Significant | - | - | 0.43 |
Azimian et al. | OK | Significant | -0.69 | -0.63 | - |
Valko et al. | OK | Significant | - | - | - |
Non MS Patients | |||||
Katsarou et al. | OK | Significant | -0.39 | - | 0.40 |
Ferentinos et al. OK | Significant | -0.52 | - | - | |
Mattsson et al. | OK | Significant | -0.63 | - | - |
Kleinman et al. | OK | - | -0.76 | - | - |